Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC/Rx Sodium Phosphate Laxative Claim Dispute Referred By NAD

This article was originally published in The Tan Sheet

Executive Summary

InKline Pharmaceuticals, which sells Rx sodium phosphate tablets, has declined to participate in the NAD self-regulatory forum, maintaining NAD is not the proper authority to review its marketing claims

You may also be interested in...

Allegra Ad State Law Portrayal Misleading When Applied To Benadryl – W-L

A DTC radio ad for Aventis' Rx antihistamine Allegra (fexofenadine) misrepresents state laws concerning driving impairment when referring to Pfizer/Warner-Lambert Consumer Group's Benadryl, the firm alleges in a case to appear in an upcoming NAD Case Reports

Novartis Transderm Scop Comparative Claims With Dramamine Denied By NAD

DTC ad claims for Novartis' Rx Transderm Scop declaring superiority to Pharmacia's OTC motion sickness remedy Dramamine are inappropriate due to "very significant differences" between the scopolamine patch's consumer-targeted claims and original FDA-reviewed statements, NAD states Nov. 8.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts